Stockscreener 앱 받기
1.11
1.34%
-0.01
Immunic Inc 주식(IMUX)의 최신 뉴스
36,811 Shares in Immunic, Inc. (NASDAQ:IMUX) Acquired by Invesco Ltd. - Defense World
Where Do Analysts See Immunic Inc (NASDAQ: IMUX) Heading? - Stocksregister
Renaissance Technologies LLC Grows Position in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Immunic’s (IMUX) Buy Rating Reiterated at D. Boral Capital - Defense World
Immunic (NASDAQ:IMUX) Earns Buy Rating from HC Wainwright - Defense World
Immunic to Participate in Scientific and Industry Conferences in May | IMUX Stock News - GuruFocus
Immunic Reveals New Clinical Data for Celiac Disease and MS Drugs at Three Major Medical Conferences - Stock Titan
Immunic presses ahead with MS drug despite Phase II endpoint miss - Yahoo Finance
IMUX: HC Wainwright & Co. Reiterates "Buy" Rating with $10.00 Pr - GuruFocus
What is Immunic Inc (IMUX) Stock Return on Shareholders’ Capital? - Sete News
Daily Progress: Immunic Inc (IMUX) Drop -22.65, Closing at 0.99 - DWinneX
MS drug shows promise in progressive cases, despite missed trial goal - The Pharma Letter
Immunic (IMUX) Price Target Raised to $22 by Brookline Following Positive Trial Data | IMUX Stock News - GuruFocus
Immunic Inc (IMUX) rating initates by William Blair - knoxdaily.com
How will Immunic Inc’s (IMUX) earnings compare to estimates this quarter? - uspostnews.com
Small cap wrap: ReconAfrica, Power Metallic, Immunic, Replenish Nutrients... - Proactive Investors
Immunic’s stock falls on multiple sclerosis data; Entrada’s layoffs - Endpoints News
Immunic Announces Vidofludimus Calcium Reduced Risk of Disabilit - GuruFocus
Immunic reports reduced disability worsening in progressive multiple sclerosis trial - Proactive Investors
Immunic (IMUX) Reports Promising Phase 2 Results for Vidofludimu - GuruFocus
Immunic (IMUX) Shares Fall on Phase 2 Trial Results for Multiple Sclerosis Drug - GuruFocus
Immunic Announces Vidofludimus Calcium Reduced Risk Of Disability Worsening By 30% In Primary Progressive Multiple Sclerosis Patients From Phase 2 Calliper Trial - marketscreener.com
Immunic stock drops after mid-stage trial data (IMUX:NASDAQ) - Seeking Alpha
Immunic Inc Inc. (IMUX) Price Performance: A Technical Analysis Perspective - investchronicle.com
Immunic reports progress in multiple sclerosis trial - Investing.com
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial | IMUX Stock News - GuruFocus
Breakthrough in Primary Progressive MS: Clinical Trial Shows 30% Reduced Disability Risk - Stock Titan
Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher (NASDAQ:IMUX) - Seeking Alpha
Immunic Inc (IMUX) Offers An Excellent Investment Opportunity At Current Levels - Stocksregister
One Immunic Insider Raised Their Stake In The Previous Year - Yahoo Finance
Trading Day Review: Immunic Inc (IMUX) Gains Momentum, Closing at 1.14 - DWinneX
Brokerages Set Immunic, Inc. (NASDAQ:IMUX) Price Target at $13.20 - Defense World
IMUX: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Immunic Inc (IMUX) stock on the rise: An overview - uspostnews.com
Immunic’s (IMUX) Buy Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Has Optimistic View of Immunic FY2025 Earnings - Defense World
HC Wainwright Estimates Immunic’s Q1 Earnings (NASDAQ:IMUX) - Defense World
Immunic, Inc. (NASDAQ:IMUX) Is Expected To Breakeven In The Near Future - simplywall.st
Immunic Stock Price, Quotes and Forecasts | NASDAQ:IMUX - Benzinga
Immunic, Inc. Announces Closing of $5.1 Million Registered Direc - GuruFocus
Immunic Stock Draws Investor Attention On $5.1M Registered Direct Offering: Retail’s On Wait-And-Watch Mode - MSN
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - The Malaysian Reserve
Immunic Closes of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - citybiz
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - Eastern Progress
Immunic Raises $5.1 Million From Direct Stock Offering - marketscreener.com
Immunic Lands Strategic $5.1M Financing Deal: Aberdeen Investments Takes Lead Position - Stock Titan
Immunic closes $5.1M placement - Proactive Investors
Immunic announces pricing of $5.1M registered direct offering - MSN
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direc - GuruFocus
Immunic Announces $5.1 Million Securities Purchase Agreement - MSN
Immunic sets $5.1 million stock offering price By Investing.com - Investing.com Canada
Immunic sets $5.1 million stock offering price - Investing.com Australia
Immunic announces pricing of $5.1M direct offering to support clinical pipeline - Proactive financial news
Immunic Announces Pricing Of $5.1 Million Registered Direct Offering - marketscreener.com
1.72%
0.85%
자본화:
|
볼륨(24시간):